ARTICLE | Translation in Brief
Early explorers
MedImmune and UCSF collaborate on early stage translational research
January 21, 2016 8:00 AM UTC
Building on a partnership established in 2014, AstraZeneca plc (LSE:AZN; NYSE:AZN)'s MedImmune LLC biologics unit and the University of California San Francisco (UCSF) announced a new collaboration focused on basic and translational research in respiratory disease, inflammation and autoimmunity.
Through the original collaboration, MedImmune became the first industry partner for UCSF's Catalyst Awards program, which selects and supports research projects from the university that have commercial applications. (See "Herding Catalysts at UCSF." SciBX: Science-Business eXchange (Feb. 27, 2014)) Now, the partners are expanding their relationship to better understand the underlying causes of disease. ...